These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17953775)

  • 21. Emergence and transmission of amantadine-resistant influenza A in a nursing home.
    Schilling M; Gravenstein S; Drinka P; Cox N; Krause P; Povinelli L; Shult P
    J Am Geriatr Soc; 2004 Dec; 52(12):2069-73. PubMed ID: 15571544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pandemic avian influenza.
    Mermel LA
    Lancet Infect Dis; 2005 Nov; 5(11):666-7. PubMed ID: 16253881
    [No Abstract]   [Full Text] [Related]  

  • 23. Developing model-based public health policy through knowledge translation: the need for a 'Communities of Practice'.
    Driedger SM; Cooper EJ; Moghadas SM
    Public Health; 2014 Jun; 128(6):561-7. PubMed ID: 24461909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting pandemic influenza: a primer on influenza antivirals and drug resistance.
    Moss RB; Davey RT; Steigbigel RT; Fang F
    J Antimicrob Chemother; 2010 Jun; 65(6):1086-93. PubMed ID: 20375034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread.
    Handel A; Longini IM; Antia R
    PLoS Comput Biol; 2007 Dec; 3(12):e240. PubMed ID: 18069885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model.
    Hurt AC; Nor'e SS; McCaw JM; Fryer HR; Mosse J; McLean AR; Barr IG
    J Virol; 2010 Sep; 84(18):9427-38. PubMed ID: 20631138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A hospital-based strategy for setting priorities for antiviral prophylaxis during an influenza pandemic.
    Hsu EB; Millin MG
    Biosecur Bioterror; 2008 Jun; 6(2):171-8. PubMed ID: 18563994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimated impact of aggressive empirical antiviral treatment in containing an outbreak of pandemic influenza H1N1 in an isolated First Nations community.
    Xiao Y; Patel Z; Fiddler A; Yuan L; Delvin ME; Fisman DN
    Influenza Other Respir Viruses; 2013 Nov; 7(6):1409-15. PubMed ID: 23879801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiviral agents for influenza: molecular targets, concerns of resistance, and new treatment options.
    Maltezou HC; Tsiodras S
    Curr Drug Targets; 2009 Oct; 10(10):1041-8. PubMed ID: 19860646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Role of antiviral drugs in containing pandemic influenza. Contribution of recent modelling exercises synthesis prepared by the InVS/Inserm "epidemiology" group - November 2005].
    Lévy-Bruhl D
    Med Mal Infect; 2006 Sep; 36(9):449-53. PubMed ID: 17027218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of population structure on the emergence of drug resistance during influenza pandemics.
    Débarre F; Bonhoeffer S; Regoes RR
    J R Soc Interface; 2007 Oct; 4(16):893-906. PubMed ID: 17609176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Public health management of pandemic (H1N1) 2009 infection in Australia: a failure!
    Waterer GW; Hui DS; Jenkins CR
    Respirology; 2010 Jan; 15(1):51-6. PubMed ID: 20199635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of prophylaxis of healthcare workers on influenza pandemic burden.
    Gardam M; Liang D; Moghadas SM; Wu J; Zeng Q; Zhu H
    J R Soc Interface; 2007 Aug; 4(15):727-34. PubMed ID: 17360253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing treatment regimes to hinder antiviral resistance in influenza across time scales.
    Patterson-Lomba O; Althouse BM; Goerg GM; Hébert-Dufresne L
    PLoS One; 2013; 8(3):e59529. PubMed ID: 23555694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
    Foffi G; Pastore A; Piazza F; Temussi PA
    Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influenza a (H1N1) outbreak and challenges for pharmacotherapy.
    Chawla R; Sharma RK; Bhardwaj JR
    Indian J Physiol Pharmacol; 2009; 53(2):113-26. PubMed ID: 20112815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Letter to the editor: Influenza antiviral susceptibility monitoring activities in relation to national antiviral stockpiles in Europe during the winter 2006/2007 season.
    Ciancio BC; Nicoll A
    Euro Surveill; 2007 Jun; 12(6):E070628.4; author reply E070628.5. PubMed ID: 17868571
    [No Abstract]   [Full Text] [Related]  

  • 38. Seasonal and pandemic influenza: a 2007 update on challenges and solutions.
    Monto AS; Whitley RJ
    Clin Infect Dis; 2008 Apr; 46(7):1024-31. PubMed ID: 18444819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence of antiviral drug resistance markers among human influenza A viruses in the Eastern Mediterranean Region, 2005-2016.
    Moasser E; Moasser A; Zaraket H
    Infect Genet Evol; 2019 Jan; 67():60-66. PubMed ID: 30389548
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.